Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of ABBV-382 in Healthy Chinese Adults
NCT06632938Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Primary completion
- May 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of ABBV-382 in Crohn's disease and human immunodeficiency virus infection (HIV) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events (AEs) at Day 140, Maximum Observed Serum Concentration (Cmax) of ABBV-382 at Day 112 and 6 more. Started Oct 2024; status: completed.
02
Drugs
ABBV-382
03
Conditions
Crohn's diseasehuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06632938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06632938.